Jubilant Pharmova subsidiary lands ₹107.89 cr tax demand
A transfer pricing order for FY23 hits the subsidiary, forcing a ₹37.70 cr write-down of deferred tax assets.
— 3 earlier stories on Jubilant Pharmova Ltd. →What's new with Jubilant Pharmova Ltd.
- Jubilant Pharmova’s subsidiary faces a ₹107.89 cr tax order, mainly from FY23 transfer pricing adjustments.
- The demand triggers a ₹37.70 cr reduction in deferred tax assets on the books.
- Management labels the claims unfounded and plans to seek relief via the Advance Pricing Authority.
Why this matters for Jubilant Pharmova Ltd.
The demand equals 27% of projected FY26 net profit, making it a meaningful distraction for a mid-cap. However, the company's aggressive contest and reliance on the Advance Pricing Authority suggest a low risk of an immediate cash drain.
What we're watching
- Outcome of the pending appeals and the Advance Pricing Authority application.
- Whether the tax department seeks further adjustments for subsequent years.
- Cash-flow impact if the dispute drags beyond near-term guidance.
The full read
Jubilant Pharmova is fighting a ₹107.89 crore tax demand levied against its subsidiary. The order stems from transfer pricing adjustments for FY23.
It is a common but messy source of friction in pharmaceutical accounting. While the amount is significant enough to require a ₹37.70 crore write-down of deferred tax assets, it does not immediately threaten the firm's core operations or growth path in any material way, and management maintains the adjustments are entirely baseless, as they push for relief through both standard appeals and a formal application to the Advance Pricing Authority to settle the matter once and for all.
Given the company is actively contesting the liability, an eventual cash outflow remains unlikely for now. The next test is whether the Advance Pricing Authority validates the firm's transfer pricing model, which would effectively resolve the demand. Until then, it is a legal contest rather than a liquidity crisis.